INmune Bio, Inc. (INMB) Misses Q2 EPS by 65c

INmune Bio, Inc. (NASDAQ: INMB) reported Q2 EPS of ($1.05), $0.65 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
• Zscaler (ZS) Reiterated at Overweight by Cantor Fitzgerald: Bullish on Red Canary Synergies